Nuvectis Pharma

NVCT · Nasdaq · United States

Share price · NVCT

$20.29-0.62 (-2.97%) 3M

close as of 2026-11-18 · 24h delayed · vol 190K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NVCT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+17.7%
  2. 4 Nov 2026-4.5%
  3. 26 Oct 2026-7.8%
  4. 30 Jun 2026-35.5%
  5. 24 Jun 2026+39.5%
  6. 22 Jun 2026+19.6%
  7. 18 Jun 2026+9.8%
  8. 16 Jun 2026+7.1%
  9. 15 May 2026-11.3%
  10. 13 May 2026+10.5%

Share of unusual movement by asset

For each asset, the share of NVCT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—25%
Sessions with no dated event—75%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
SRC and YES1 (Src-family kinases)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$27M$141M$30M-$25M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$4.7M$22M$7.0M-$4.5M operating cash flowreport ↗
2026-Q1—$4.1M$25M$6.0M-$6.5M operating cash flowreport ↗
2025-Q3—$5.8M$35M$7.5M-$4.5M operating cash flowreport ↗
2025-Q2—$3.6M$27M$6.3M-$3.4M operating cash flowreport ↗
2025-Q1—$3.7M$30M$5.3M-$4.2M operating cash flowreport ↗
2024-Q3—$2.8M$17M$4.2M-$2.4M operating cash flowreport ↗
2024-Q2—$2.9M$18M$4.4M-$3.0M operating cash flowreport ↗
2024-Q1—$2.7M$19M$4.2M-$4.4M operating cash flowreport ↗
2023-Q3—$4.5M$22M$5.9M-$3.2M operating cash flowreport ↗
2023-Q2—$4.3M$25M$5.7M-$4.1M operating cash flowreport ↗
2023-Q1—$2.4M$15M$4.0M-$4.8M operating cash flowreport ↗
2022-Q3—$4.5M$24M$5.9M-$4.4M operating cash flowreport ↗
2022-Q2—$2.5M$14M$3.6M-$2.5M operating cash flowreport ↗
2022-Q1—$1.8M$17M$2.9M-$3.1M operating cash flowreport ↗
2021-Q3—$4.2M$6.8M$4.7M-$4.4M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$18M$32M$26Mreport ↗

For fiscal 2025, Nuvectis Pharma reported revenue of $0M (prior year $0M), R&D spend of $18.2M, up 41.1% YoY, and cash and cash equivalents of $31.6M at year-end. The company reported a net loss of $26.4M for the year, compared with $19.0M in 2024, with the increase including $6.0M in non-cash stock-based compensation and $2.4M in one-time milestone license fees.

Nuvectis is advancing NXP900, an oral small-molecule SFK inhibitor that has completed Phase 1a dose escalation; the Phase 1b monotherapy study and a Phase 1b combination with osimertinib in EGFR-mutated non-small cell lung cancer are enrolling, and a combination with lorlatinib in ALK-positive NSCLC is pending commencement. Management expects multiple potential NXP900 Phase 1b data readouts in 2026 and states that current cash is expected to support operations through multiple potential Phase 1b milestones and well into the second half of 2027.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$13M$19M$19Mreport ↗
2023-FY$0$15M$19M$22Mreport ↗
2022-FY—$13M$20M$4.8M-$14M operating cash flowreport ↗
2021-FY—$9.6M$5.7M$3.2M-$9.5M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($1.2M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-03Carson Michael J. · Vice President, FinanceAward / grant30,000——Form 4
2026-06-30BENTSUR RON · director, Chairman & CEO, 10% ownerOpen-market purchase12,500$20.00$250KForm 4
2026-06-30Mosseri Marlio Charles · 10% ownerOpen-market purchase50,000$18.32$916KForm 4
2026-06-11Kaplan Matthew L. · directorAward / grant35,000——Form 4
2026-06-11Sanchez Juan · directorAward / grant35,000——Form 4
2026-06-11Oliviero James F III · directorAward / grant35,000——Form 4
2026-06-11Hoberman Kenneth · directorAward / grant35,000——Form 4
2026-01-06Carson Michael J. · Vice President, FinanceAward / grant61,200——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 61 reporting institutions held 4.4M shares ($34.2M, 12.9% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.764,441$5.9M
2VANGUARD CAPITAL MANAGEMENT LLC659,879$5.1M
3IRIDIAN ASSET MANAGEMENT LLC/CT651,757$5.0M
4Occam Crest Management LP407,147$3.1M
5GEODE CAPITAL MANAGEMENT, LLC384,105$3.0M
6BALDWIN WEALTH PARTNERS LLC/MA378,625$2.9M
7STATE STREET CORP166,516$1.3M
8NORTHERN TRUST CORP124,212$960K
9VANGUARD FIDUCIARY TRUST CO114,842$888K
10SUSQUEHANNA INTERNATIONAL GROUP, LLP105,286$814K
11VANGUARD PORTFOLIO MANAGEMENT LLC92,154$712K
12CITADEL ADVISORS LLC78,425$606K
13OPPENHEIMER & CO INC73,566$569K
14CHARLES SCHWAB INVESTMENT MANAGEMENT INC49,645$384K
15GOLDMAN SACHS GROUP INC41,124$318K